News InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904 Continue Reading Previous InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904Next Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors Related Stories News EnviroMetal Settles Outstanding Liabilities News Hyper Bit Technologies Announces Private Placement News Coloured Ties Capital Announces Proposed Share Consolidation News EarthLabs Adopts New Equity Compensation Plan News SATO Technologies Signs Letter of Intent with Bhutan’s Gelephu Mindfulness City Authority to Develop a Hydro-Powered Sovereign AI Compute Campus News Agereh Technologies Appoints Airport Operations and Defence Technology Advisors to Support Infrastructure and Dual-Use Market Expansion
